Visão geral da empresa
A biopharmaceutical entity dedicated to the development and commercialization of novel therapies targeting high unmet medical needs globally, Vanda Pharmaceuticals Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high reliance on research and development alongside regulatory compliance. The company manages a commercial portfolio that includes Fanapt, a therapy designed for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Currently, the organization employs a workforce of 533 individuals and holds a market capitalization of $430.90M with a trailing twelve-month revenue of $216.10M. These valuation and revenue figures indicate that the company is a mid-sized market participant that has achieved significant commercial traction but remains in a capital-intensive growth phase typical for specialized biotechnology firms.
Saúde financeira
Vanda Pharmaceuticals reported a revenue of $216.10M over the trailing twelve months, yet it recorded a net income loss of $-220,474,000 and an EBITDA of $-143,058,000. The substantial gap between the positive revenue and negative net income reveals a cost structure where operating expenses, likely driven by research, development, and commercialization efforts, significantly exceed the gross profit generated from sales. The company generated a free cash flow of $-49,359,000, which indicates a current state of cash burn that necessitates continued financing to sustain operations until future product milestones are reached or profitability is achieved. Margin analysis shows a gross margin of 94.0%, reflecting high pricing power or low cost of goods sold, contrasted by an operating margin of -70.5% and a profit margin of -102.0% that highlight the intense overhead costs consuming the bottom line. The balance sheet displays $263.85M in cash against $12.62M in debt, supported by a debt-to-equity ratio of 3.86, suggesting a leveraged capital structure where equity is used to finance significant liabilities despite the high cash on hand. Liquidity is robust, evidenced by a current ratio of 2.39, indicating that the company holds more than double the current assets necessary to cover its short-term obligations. Return metrics show a return on equity of -50.9% and a return on assets of -16.5%, which collectively reveal that management effectiveness is currently challenged by the company's inability to generate positive returns on its capital base due to ongoing operational deficits.
Avaliação de valorização
Valuation multiples present a mixed picture given the lack of consistent earnings, with a trailing P/E ratio of N/A and a forward P/E of 36.45. The absence of a trailing P/E due to negative earnings combined with a forward P/E of 36.45 implies that the market is pricing in future earnings expectations that have not yet materialized, suggesting a high expectation for turnaround or growth in profitability. The price-to-book ratio stands at 1.32, indicating that the market values the company at a 32% premium over its net asset value, which may reflect intangible assets or potential value in the drug pipeline not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 1.99 and an EV/EBITDA of -1.26, suggesting the company is valued based on revenue generation rather than earnings power, a common practice for unprofitable biotechs. The stock's trading range over the last year spans from a 52-week low of $3.81 to a 52-week high of $9.94. Without a specific current price listed in the provided facts, the precise percentage deviation from the high or low cannot be calculated, but the wide spread between $3.81 and $9.94 demonstrates significant intrayear volatility. The stock exhibits a beta of 0.71, meaning its price volatility is historically lower than the broader market, moving less aggressively than the S&P 500 during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year stands at 7.6%, while earnings growth is N/A due to the company's continued net losses. The fact that revenue is growing while earnings remain negative implies that top-line expansion is occurring without yet translating to profitability, a standard trajectory for commercializing new therapies before achieving full market penetration or cost efficiency. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash and earnings are reinvested directly into research, development, and commercial operations rather than being distributed to shareholders. This reinvestment strategy is essential for funding the pipeline and sustaining the cash burn required to bring new assets to market. Overall, the company presents a profile of steady revenue expansion coupled with persistent losses and no income distribution, characteristic of a growth-stage biopharmaceutical firm prioritizing long-term product development over immediate shareholder returns.